GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC

BACKGROUND: Immunotherapy drugs, immune checkpoint inhibitors (ICIs), have been approved for first- and second-line treatment of non-small cell lung cancer (NSCLC), but only a portion of patients respond to ICIs. It is crucial to screen the beneficiaries of immunotherapy through biomarkers accuratel...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Honghong, Shi, Yuxin, Wang, Huiyu, Li, Yuting, Mei, Jie, Xu, Junying, Liu, Chaoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183185/
https://www.ncbi.nlm.nih.gov/pubmed/37193249
http://dx.doi.org/10.2147/IJGM.S408900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183185/
https://www.ncbi.nlm.nih.gov/pubmed/37193249
http://dx.doi.org/10.2147/IJGM.S408900

Ejemplares similares